


Amendments to the Claims

1-2. (Cancelled)


3. (Original) A pharmaceutical composition used for treatment or prevention of brain injury comprising an antagonist for prostaglandin D receptor as an effective ingredient.

4. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is (\pm)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2- hydroxyethylamino)-hydantoin, (+)-(3R)-3-(4-fluorobenzenesulfonamide)-1,2,3,4-tetrahydrocarbazol-9- propionic acid, (Z)-7-[(1R,2R,3S,5S)-2-(5- hydroxybenzo[b]thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid, (Z)-7-[(1R,2R,3S,5S)-2-(benzo[b]- thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid and pharmaceutically acceptable salt thereof and hydrate thereof.

5. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (I)




(wherein,



R is hydrogen, alkyl, alkoxy, halogen, hydroxyl, acyloxy or optionally substituted arylsulfonyloxy; X is hydrogen or alkyl; and a double bond of an α -chain is in an E-


configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

6. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA)



(wherein R and X have the same meanings as defined already and a double bond of an α -chain is in an E-configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

7. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA-a)



(wherein R and X have the same meanings as defined already and a double bond of an α -chain is in an E-configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

8-9. (Cancelled)

10. (Original) A method for treatment of brain injury comprising administration of a prostaglandin D receptor antagonist of an effective dose.

11. (Original) A use of a prostaglandin D receptor antagonist for the manufacture of a drug for treatment of brain injury.

12-13. (Cancelled)